RSS   Newsletter   Contact   Advertise with us

Pernix Therapeutics appoints Tasos Konidaris to its board

Staff writer | Morristown, NJ, USA – Pernix Therapeutics Holdings, Inc., a specialty pharmaceutical company, announced the appointment of Tasos Konidaris as a non | April 29, 2014
Pernix TherapeuticsApril 29, 2014, Morristown, NJ, USA – Pernix Therapeutics Holdings, Inc., a specialty pharmaceutical company, announced the appointment of Tasos Konidaris as a non-executive director and as chairman of the audit committee.
Mr. Konidaris has served as Senior Vice President and Chief Financial Officer of Ikaria, Inc., a biotherapeutics company, since October 2011. Prior to joining Ikaria, since 2007, Mr. Konidaris served as Senior Vice President and Chief Financial Officer at Dun & Bradstreet (D&B) Corporation, a commercial information services company. He was Principal Accounting Officer and led the Global Finance Operations of D&B beginning in 2005.

From 2003 to 2005, Mr. Konidaris served as Group Vice President of the Global Pharmaceutical and Global Diversified Products Groups at Schering-Plough Corporation, a pharmaceutical company.

Earlier in his career, Mr. Konidaris held senior financial and operational positions of increasing responsibility at the Pharmacia Corporation, Rhone-Poulenc Rorer, Novartis Corporation and Bristol-Myers Squibb Company. Mr. Konidaris holds an MBA from Drexel University, and a BS from Gwynedd Mercy College.


 LATEST MOVES FROM  


MORE INSIDE POST